18 results
425
EX-99.2
INFIQ
Infinity Pharmaceuticals, Inc.
20 Jun 23
Business combination disclosure
8:02am
cells need significant amounts of energy to grow, and can switch between mitochondria and glycolytic metabolic pathways to escape the blocking of either … Proof of Concept of ME-344 as a Novel Mitochondrial Inhibitor with the Potential to Prevent Anti-Angiogenic Escape in Combination with Bevacizumab 79
8-K
EX-99.2
INFIQ
Infinity Pharmaceuticals, Inc.
20 Jun 23
Overview and Update on Pending Merger to Advance Three Promising Clinical
8:00am
cells need significant amounts of energy to grow, and can switch between mitochondria and glycolytic metabolic pathways to escape the blocking of either … Proof of Concept of ME-344 as a Novel Mitochondrial Inhibitor with the Potential to Prevent Anti-Angiogenic Escape in Combination with Bevacizumab 79
8-K
EX-10.8
INFIQ
Infinity Pharmaceuticals, Inc.
18 Sep 06
Infinity Pharmaceuticals Announces Completion of Merger with Discovery Partners International
12:00am
the presence on or under or the escape, seepage, leakage, spillage, discharge, emission or release of any Hazardous Materials on the premises owned
424B4
INFIQ
Infinity Pharmaceuticals, Inc.
6 May 04
Prospectus supplement with pricing info
12:00am
of it without allowing the compound being synthesized inside to escape. In this way, we can process tens, hundreds or even thousands of micro
424A
e19gq 12hg5cv31vq
15 Apr 04
Prospectus with significant changes
12:00am
S-3
hrktwn0llh
10 Mar 04
Shelf registration
12:00am
10-K
kmuu oyf9z4j
29 Mar 02
Annual report
12:00am
10-K405
qdu1f2ievhchmffjmyx
27 Mar 01
Annual report (delinquent filer disclosure)
12:00am
424B4
j59mq
28 Jul 00
Prospectus supplement with pricing info
12:00am
S-1/A
tqm672gmsf2
23 Jun 00
IPO registration (amended)
12:00am
S-1
kn8sgtz7tdlky
9 May 00
IPO registration
12:00am
- Prev
- 1
- Next